21 Firstfield Road
Gaithersburg, MD 20878
United States
240 268 2000
https://www.novavax.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,992
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. James Patrick Kelly C.F.A. | Exec. VP, CFO & Treasurer | 355.23k | N/A | 1966 |
Mr. John A. Herrmann III | Exec. VP, Chief Legal Officer & Corp. Sec. | 657.8k | 14.2M | 1966 |
Mr. Stanley Charles Erck | Advisor | 1.12M | 28.63M | 1948 |
Mr. John Joseph Trizzino B.S., M.B.A. | Exec. VP and Chief Bus. & Commercial Officer | 636.85k | 13.33M | 1960 |
Dr. Gregory M. Glenn M.D. | Pres of R&D | 813.44k | 29.02M | 1954 |
Mr. John Charles Jacobs M.B.A. | Pres, CEO & Director | N/A | N/A | 1968 |
Mr. Richard P. Crowley | Exec. VP & COO | N/A | N/A | 1957 |
Dr. Gale E. Smith | Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist | N/A | N/A | 1950 |
Mr. Biegie Lee | Sr. VP & Chief Information Officer | N/A | N/A | N/A |
Mr. Troy Morgan Esq., J.D. | Sr. VP & Chief Compliance Officer | N/A | N/A | 1971 |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax, Inc.’s ISS governance QualityScore as of 1 March 2023 is 5. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 5; Compensation: 6.